Proposal for a new protein therapeutic immunogenicity titer assay cutpoint

Bioanalysis. 2011 Dec;3(23):2627-36. doi: 10.4155/bio.11.273.

Abstract

Background: Generally, immunogenicity assessment strategies follow this assay triage schema: screen→confirm→titer. Each requires the determination of a threshold value (cutpoint) for decision making. No guidance documents exist for the determination of a specific titration assay cutpoint. The default practice is to use the screening assay cutpoint, frequently leading to controls or samples not reaching this cutpoint. We propose a method for determination of a titration cutpoint based upon the variance of the negative-control sample.

Results: Positive-control samples that did not cross a screening cutpoint did cross the titer cutpoint, albeit generating slightly lower titer values.

Conclusion: Our approach is consistent with the statistical methods currently recommended for the screening and confirmatory assay cutpoints and is operationally simple and efficient.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Antibodies, Monoclonal, Humanized / analysis*
  • Antibodies, Monoclonal, Humanized / immunology
  • Computer Simulation
  • Data Interpretation, Statistical
  • Humans
  • Immunogenetic Phenomena
  • Immunologic Techniques / methods*
  • Immunologic Tests
  • Models, Immunological
  • Proteins / immunology*
  • Reproducibility of Results

Substances

  • Antibodies, Monoclonal, Humanized
  • Proteins
  • ocrelizumab